Emerald Advisers LLC Acquires 165,085 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Emerald Advisers LLC raised its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 8.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,125,744 shares of the company’s stock after buying an additional 165,085 shares during the period. Travere Therapeutics accounts for approximately 1.4% of Emerald Advisers LLC’s portfolio, making the stock its 13th biggest holding. Emerald Advisers LLC owned 2.72% of Travere Therapeutics worth $37,030,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in TVTX. Rhumbline Advisers lifted its position in Travere Therapeutics by 2.2% during the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company’s stock worth $2,112,000 after acquiring an additional 2,640 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Travere Therapeutics by 13.5% in the fourth quarter. Arizona State Retirement System now owns 22,396 shares of the company’s stock worth $390,000 after purchasing an additional 2,666 shares during the period. R Squared Ltd bought a new position in shares of Travere Therapeutics in the fourth quarter worth about $53,000. Diversified Trust Co increased its stake in shares of Travere Therapeutics by 27.5% in the fourth quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock worth $256,000 after purchasing an additional 3,169 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Travere Therapeutics by 20.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company’s stock worth $279,000 after purchasing an additional 3,458 shares during the period.

Analysts Set New Price Targets

TVTX has been the topic of a number of recent analyst reports. Citigroup lifted their price objective on Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Evercore ISI lifted their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price objective on Travere Therapeutics from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Finally, HC Wainwright lifted their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.62.

Travere Therapeutics Stock Down 1.4 %

NASDAQ TVTX opened at $20.53 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The stock’s 50 day moving average is $20.50 and its two-hundred day moving average is $18.16. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -5.01 and a beta of 0.75. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). The company had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. Equities analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Insider Transactions at Travere Therapeutics

In other news, CAO Sandra Calvin sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at $945,842.94. The trade was a 21.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jula Inrig sold 2,066 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total value of $39,460.60. Following the completion of the transaction, the insider now directly owns 59,883 shares in the company, valued at $1,143,765.30. The trade was a 3.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 206,335 shares of company stock valued at $4,453,012 in the last three months. 3.75% of the stock is owned by corporate insiders.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.